STAAR Surgical (NASDAQ:STAA) Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. lessened its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 6.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,022 shares of the medical instruments supplier’s stock after selling 1,570 shares during the period. Fox Run Management L.L.C.’s holdings in STAAR Surgical were worth $559,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of STAA. Geode Capital Management LLC boosted its position in STAAR Surgical by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after purchasing an additional 31,212 shares in the last quarter. HighTower Advisors LLC purchased a new stake in shares of STAAR Surgical in the 3rd quarter worth about $336,000. Polar Asset Management Partners Inc. grew its stake in STAAR Surgical by 44.3% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier’s stock valued at $6,271,000 after acquiring an additional 51,800 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in STAAR Surgical by 411.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after acquiring an additional 172,779 shares in the last quarter. Finally, Defender Capital LLC. increased its holdings in STAAR Surgical by 3.5% during the 4th quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier’s stock valued at $17,041,000 after acquiring an additional 23,950 shares in the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on STAA shares. Canaccord Genuity Group reduced their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Stephens restated an “equal weight” rating and set a $17.00 price objective on shares of STAAR Surgical in a report on Tuesday, March 18th. StockNews.com lowered STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Thursday, February 13th. William Blair lowered STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. Finally, Stifel Nicolaus lowered their price target on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $25.29.

Insider Transactions at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 108,720 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The shares were purchased at an average price of $17.96 per share, for a total transaction of $1,952,611.20. Following the completion of the purchase, the insider now directly owns 12,182,995 shares in the company, valued at $218,806,590.20. The trade was a 0.90 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. In the last three months, insiders have acquired 1,036,187 shares of company stock worth $17,239,548. 1.00% of the stock is currently owned by insiders.

STAAR Surgical Price Performance

Shares of STAA opened at $17.77 on Tuesday. The stock has a market capitalization of $876.51 million, a PE ratio of -43.34 and a beta of 0.66. The business’s fifty day moving average price is $19.77 and its 200 day moving average price is $25.52. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $52.68.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.